Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.

Human genomics - 24 Apr 2024

Ouyang Yuzhen, Chen Yu, Chen Kangzhi, Tang Zhenwei, Shi Guanzhong, Qu Chunrun, Zhang Kaiyue, Yang Huan

Abstract excerpt

OBJECTIVE: Myasthenia gravis (MG) is a complex autoimmune disease affecting the neuromuscular junction with limited drug options, but the field of MG treatment recently benefits from novel biological agents. We performed a drug-targeted Mendelian randomization (MR) study to identify novel therapeutic targets of MG. METHODS: Cis-expression quantitative loci (cis-eQTL), which proxy expression levels for 2176...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Neurological Disorders and Treatments
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mendelian Randomization Analysis

Share to Myasthenia Gravis

Share to Myasthenia Gravis and Thymoma

Share to Polymorphism, Single Nucleotide

Share to Protein Interaction Maps

Share to Quantitative Trait Loci

Source

Open in PubMed Open full text

Identifiers

PMID: 38659056
DOI: 10.1186/s40246-024-00607-7
PMCID: PMC11040902

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis.PMID 38659056Read ↗

Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis.Semantic proximity Read ↗

Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravisSemantic proximity Read ↗

Integration of genomic variants and bioinformatic-based approach to drive drug repurposing for multiple sclerosisSemantic proximity Read ↗

Multi-omics integration prioritizes potential drug targets for multiple sclerosisSemantic proximity Read ↗

Circulating inflammatory cytokines and the risk of myasthenia gravis: a bidirectional Mendelian randomization studySemantic proximity Read ↗

Therapeutic Targets for Multiple System AtrophySemantic proximity Read ↗

Construction of a TF–miRNA–gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravisSemantic proximity Read ↗

Identification of drug targets for Sjögren's syndrome: multi-omics Mendelian randomization and colocalization analyses.Semantic proximity Read ↗

Summary-data-based mendelian randomisation reveals druggable targets for multiple sclerosisSemantic proximity Read ↗

Integrating Genomic, eQTL, and Mendelian Randomization Analyses to Identify Microglial Drug Targets in Multiple Sclerosis.Semantic proximity Read ↗

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitroSemantic proximity Read ↗

Leveraging pQTL-based Mendelian randomization to identify new treatment prospects for primary biliary cholangitis and primary sclerosing cholangitis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.